A whopping 85% of men experience significantly thinning hair by age 50, and two-thirds experience noticeable hair loss by age ...
By Sneha S K and Amina Niasse Feb 23 (Reuters) - Online telehealth company Hims & Hers Health, which sells weight-loss drugs, ...
The telehealth platform logged a quarterly profit of $20.6 million as it worked to offer a wider range of treatments and grew ...
Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.
Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here to read why HIMS is a Sell.
Hims & Hers Health, Inc., faces GLP-1 headwinds, volatility, and regulatory risk but has strong revenue growth and global ...
Shares of Hims & Hers Health (NYSE:HIMS) are trading lower this morning after yesterday’s earnings, and the reason is ...
Hims & Hers executives struck a confident tone about the company's growth prospects on Monday as it launches new specialties and expands rapidly into international markets. | Investors are concerned ...
Hims & Hers Health Inc. HIMS shares are down during Tuesday’s premarket session as the company reported mixed fourth-quarter ...
2don MSN
Hims & Hers’ expansion plans — as well as its Super Bowl ad — have investors worried about profits
The wellness platform’s results arrived amid heightened legal and regulatory scrutiny over its weight-loss-drug business.
Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft 2026 revenue ...
In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results